Predictive Nomogram for Recurrence After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2)
Ryuichi Yoshida(Okayama University), Toshiyoshi Fujiwara(Okayama University), Daisuke Nobuoka(Fukuyama City Hospital), Tatsuo Matsuda(Okayama University Hospital), Kosei Takagi(Okayama Shoka University), Susumu Shinoura(Okayama University), Toru Kojima(Okayama Saiseikai General Hospital), Yoshikatsu Endo(Himeji Red Cross Hospital), Masayoshi Hioki(Fukuyama City Hospital), Masaru Inagaki(Fukuyama Cardiovascular Hospital), Hideki Aoki(Iwakuni Medical Center), Kazuya Yasui(Okayama University), Kenta Sui(Okayama University), Masashi Kimura(Matsuyama Shimin Hospital), Takehiro Okabayashi(CHI Health)
Cited by 1
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
|Molecular Cancer Therapeutics|2021|258
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178